Sarepta Shares Rise After New Drug Results

Share prices rose in Sarepta Therapeutics (SRPT US) following release of positive clinical trial data for a drug combating Duchenne Muscular Dystrophy (DMD).  Preliminary results were better than indicated and could potentially treat 8% of patients suffering from the disease, although physicians still remained skeptical.  This opens the door for a second potential drug in Sarepta’s portfolio after the approval by the FDA of  Exondys 51 last year.

See Article